5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.
Prolactin responses to d-fenfluramine (d-FEN) challenge (0.5 mg/kg PO) were examined after pre-treatment with and without the 5-HT2a/2c receptor antagonist amesergide in eight physically healthy male volunteers. Compared to pretreatment with placebo, pre-treatment with amesergide completely blocked the prolactin (PRL) response to d-FEN challenge in all subjects. These data are consistent with data demonstrating a complete blockade of the PRL response to d-FEN with the 5-HT2a/2c receptor antagonist ritanserin, and suggest that the PRL response to d-FEN challenge in humans may largely be due to activation of the 5-HT2a/2c receptor.
Coccaro
E F
EF
Department of Psychiatry, Medical College of Pennsylvania, Philadelphia 19129, USA.
Kavoussi
R J
RJ
Oakes
M
M
Cooper
T B
TB
Hauger
R
R
D000328:Adult; D000704:Analysis of Variance; D004873:Ergolines / Q000494:pharmacology*; D005277:Fenfluramine / Q000037:antagonists & inhibitors* / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000502:physiology; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood / Q000494:pharmacology*
D004873:Ergolines; D005277:Fenfluramine; D011388:Prolactin; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; C066736:amesergide